Hims & Hers launches into Canada as country prepare for generic GLP-1 weight loss drugs

Expansion Plans - Hims and Hers is expanding its telehealth platform globally, moving from the US and UK to Germany, Spain, France, Ireland, and Canada by the end of 2025 [1] - The company has completed an all-cash acquisition of Live Well, a Canadian digital health provider focused on weight loss care, which positions Hims and Hers in a market where two-thirds of adults are living with obesity [2] Product Rollout - The acquisition sets the stage for a full rollout of weight loss products in the upcoming year, coinciding with the expected availability of the first generic semaglutide, a drug similar to Novo's blockbuster offerings [3] - The introduction of lower-cost generics is anticipated to significantly impact affordability and demand for obesity therapies [4] Market Dynamics - Hims and Hers' CEO highlighted that unbranded GLP-1s represent a unique opportunity to assess the effects of a different price point on public health, potentially pressuring major pharmaceutical companies like Novo and Eli Lilly to reduce their prices [4] - Although no supplier has been secured in Canada for the generic drugs yet, an unbranded version is expected to be approved by June 2026 at approximately half the price of branded alternatives [5]